3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Lymphoid
1
Conditions
Lymphoma, Mantle-Cell
11
Lymphoma, Non-Hodgkin
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Follicular
5
Lymphoma
5
Hodgkin Disease
5
Waldenstrom Macroglobulinemia
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Neoplasms
3
Recurrence
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Carcinoma, Renal Cell
2
Burkitt Lymphoma
2
Breast Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Soft Tissue Neoplasms
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Sarcoma
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pharyngeal Neoplasms
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Interventions
pembrolizumab
3
temsirolimus
1
spartalizumab
1
poly ICLC
1
patritumab
1
durvalumab
1
atezolizumab
1
advexin
1
Tetanus Toxoid
1
Sunitinib
1
Rifampin
1
Radiation
1
Nivolumab
1
Midazolam
1
Ketoconazole
1
Ipilimumab
1
Interleukin-15
1
Brentuximab Vedotin
1
Blood Specimen Collection
1
Axitinib
1
3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione
1
2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid
1
1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
temsirolimus
×
Lymphoid
×
Clear all
NCT00700258
2024-09-23
STAR-TOR
Pfizer
Completed
1,520 enrolled
24 charts